Mode
Text Size
Log in / Sign up
Phase 4 N=78 Treatment

MiDAS I (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study

Lumbar Spinal Stenosis

Enrolled (actual)
78
Serious AEs
0.0%
Results posted
Apr 2013
Primary outcome: Primary: Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS). — 3.21 units on a scale — p=<0.0001

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Interlaminar Decompression (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Vertos Medical, Inc.
Primary completion
Apr 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Change in Back Pain as Measured by a 10-point Visual Analog Scale (VAS).
3.21 <0.0001 sig

Summary

This is a multi-center, prospective, clinical study to assess the clinical application and outcomes of MILD® Interlaminar Decompression in patients with symptomatic lumbar spinal stenosis.

Eligibility Criteria

Inclusion Criteria

  • Symptomatic Lumbar Spinal Stenosis (LSS) primarily caused by dorsal element hypertrophy.
  • Prior failure of conservative therapy.
  • Radiologic evidence of LSS (L3-L5), Ligamentum flavum > 2.5mm, confirmed by pre-op MRI and/or CT.
  • Central canal cross sectional area ≤ 100 square mm.
  • Anterior listhesis ≤ 5.0mm.
  • Able to walk at least 10 feet unaided before being limited by pain.
  • Available to complete 12 weeks of follow-up.
  • Consistent with the intended labeling statement for use.
  • Able to use all package components to perform the procedure.
  • A signed Informed Consent Form is obtained from the patient.

Exclusion Criteria

  • Prior surgery at intended treatment level.
  • History of recent spinal fractures with concurrent pain symptoms.
  • Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).
  • Significant / symptomatic disk protrusion or osteophyte formation.
  • Excessive / symptomatic facet hypertrophy.
  • Bleeding disorders and/or current use of anti-coagulants.
  • Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment.
  • Epidural steroids within prior three weeks.
  • Inability of the patient to lie prone for any reason with anesthesia support (e.g. chronic obstructive pulmonary disease (COPD), obesity, etc.).
  • Any potential wound healing pathologies that may compromise outcomes, including diabetes, excessive smoking history, cancer, connective tissue diseases, recent spine radiation and severe COPD.
  • Dementia and/or inability to give informed consent.
  • Pregnancy.
  • Intended treatment that is defined by the product labeling contraindications.
  • On Workman's Compensation or considering litigation associated with back pain.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00956631). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search